All Issue

2021 Vol.51, Issue 2

Review Article

Association of Fusobacterium nucleatum in the Progression of Colorectal Cancer
Asma Rafique1
,
Young-Sang Koh1†
1Department of Microbiology and Immunology, College of Medicine, and Jeju Research Center for Natural Medicine, Jeju National University, Jeju 63243, Republic of Korea
*yskoh7@jejunu.ac.kr
30 June 2021. pp. 39-53
PDF XML Citation
Abstract

Colorectal cancer (CRC) is recognized as the third most common malignancy worldwide. Previous studies indicated several genetic and environmental factors that potentiate CRC. However, the role of microbiota in the etiology of CRC is becoming a major concern nowadays. Fusobacterium nucleatum (F. nucleatum), an anaerobic bacterium, mostly resides in the oral cavity and is a causative agent of various oral inflammatory diseases. It is evident from the recent studies that F. nucleatum is present in abundance in the CRC tissues as compared to the adjacent normal tissues. F. nucleatum has certain virulence factors like FadA and Fap2 which help in its adhesion to the mucosal cells and promotes carcinogenesis. Besides that, these virulence factors induce cytokine production and recruitment of inflammatory cells, hence it creates an environment favorable for neoplastic growth. Furthermore, F. nucleatum can suppress the host immune system by interfering with normal functions of macrophages, dendritic cells, T cells, tumor-associated neutrophils and natural killer cells. It was also revealed that CRC patients with high numbers of F. nucleatum showed drug resistance and cancer recurrence. From the previous investigations, it was concluded that F. nucleatum has a diagnostic as well as prognostic value for CRC patients. In the present study, we have outlined the current data on the detection methods, pathogenic mechanisms, immunosuppression effects and clinical management of F. nucleatum-associated CRC.

Keywords
Colorectal cancer
Fusobacterium nucleatum
Virulence factors
Carcinogenesis
Immunosuppression
References
1

Tam SY, Wu VWC. A Review on the Special Radiotherapy Techniques of Colorectal Cancer. Front Oncol 2019;9:208.

10.3389/fonc.2019.0020831001474PMC6454863
2

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.

10.3322/caac.2126225651787
3

Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014;383:1490-502.

10.1016/S0140-6736(13)61649-9
4

Holmes E, Li JV, Marchesi JR, Nicholson JK. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab 2012;16:559-64.

10.1016/j.cmet.2012.10.00723140640
5

Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci U S A 2003;100:10452-9.

10.1073/pnas.173406310012923294PMC193582
6

Rea D, Coppola G, Palma G, Barbieri A, Luciano A, Del Prete P, et al. Microbiota effects on cancer: from risks to therapies. Oncotarget 2018;9:17915-27.

10.18632/oncotarget.2468129707157PMC5915165
7

Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012;338:120-3.

10.1126/science.122482022903521PMC3645302
8

Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis 2011;53:870-8.

10.1093/cid/cir60921960713
9

Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 2014;33:1381-90.

10.1007/s10096-014-2081-324599709
10

Gagnière J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 2016;22:501-18.

10.3748/wjg.v22.i2.50126811603PMC4716055
11

Krishnan S, Eslick GD. Streptococcus bovis infection and colorectal neoplasia: a meta-analysis. Colorectal Dis 2014; 16:672-80.

10.1111/codi.1266224824513
12

Tsai CE, Chiu CT, Rayner CK, Wu KL, Chiu YC, Hu ML, et al. Associated factors in Streptococcus bovis bacteremia and colorectal cancer. Kaohsiung J Med Sci 2016;32:196-200.

10.1016/j.kjms.2016.03.00327185602
13

Viljoen KS, Dakshinamurthy A, Goldberg P, Blackburn JM. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PLoS One 2015;10:e0119462.

10.1371/journal.pone.011946225751261PMC4353626
14

Zhou Y, He H, Xu H, Li Y, Li Z, Du Y, et al. Association of oncogenic bacteria with colorectal cancer in South China. Oncotarget 2016;7:80794-802.

10.18632/oncotarget.1309427821805PMC5348355
15

Fukugaiti MH, Ignacio A, Fernandes MR, Ribeiro Júnior U, Nakano V, Avila-Campos MJ. High occurrence of Fusobacterium nucleatum and Clostridium difficile in the intestinal microbiota of colorectal carcinoma patients. Braz J Microbiol 2015;46:1135-40.

10.1590/S1517-83824642014066526691472PMC4704648
16

Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer 2015;137:1258-68.

10.1002/ijc.2948825703934
17

Quah SY, Bergenholtz G, Tan KS. Fusobacterium nucleatum induces cytokine production through Toll-like- receptor-independent mechanism. Int Endod J 2014;47:550-9.

10.1111/iej.1218524102075
18

Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell 2017;170:548-63.

10.1016/j.cell.2017.07.00828753429PMC5767127
19

Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14:207-15.

10.1016/j.chom.2013.07.00723954159PMC3772512
20

Sears CL, Geis AL, Housseau F. Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Invest 2014;124:4166-72.

10.1172/JCI7233425105360PMC4191034
21

Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016-22.

10.1038/nm.201519701202PMC3034219
22

Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci U S A 2011;108:15354-9.

10.1073/pnas.101020310821876161PMC3174648
23

Fujii R, Saito Y, Tokura Y, Nakagawa KI, Okuda K, Ishihara K. Characterization of bacterial flora in persistent apical periodontitis lesions. Oral Microbiol Immunol 2009;24:502-5.

10.1111/j.1399-302X.2009.00534.x19832803
24

Kistler JO, Booth V, Bradshaw DJ, Wade WG. Bacterial community development in experimental gingivitis. PLoS One 2013;8:e71227.

10.1371/journal.pone.007122723967169PMC3743832
25

Yang NY, Zhang Q, Li JL, Yang SH, Shi Q. Progression of periodontal inflammation in adolescents is associated with increased number of Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythensis, and Fusobacterium nucleatum. Int J Paediatr Dent 2014;24:226-33.

10.1111/ipd.1206524025042
26

Han YW, Fardini Y, Chen C, Iacampo KG, Peraino VA, Shamonki JM, et al. Term stillbirth caused by oral Fusobacterium nucleatum. Obstet Gynecol 2010;115:442-5.

10.1097/AOG.0b013e3181cb995520093874PMC3004155
27

Kai A, Cooke F, Antoun N, Siddharthan C, Sule O. A rare presentation of ventriculitis and brain abscess caused by Fusobacterium nucleatum. J Med Microbiol 2008;57:668-71.

10.1099/jmm.0.47710-018436604
28

Mitsuhashi K, Nosho K, Sukawa Y, Matsunaga Y, Ito M, Kurihara H, et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 2015;6:7209-20.

10.18632/oncotarget.310925797243PMC4466679
29

Yoneda M, Kato S, Mawatari H, Kirikoshi H, Imajo K, Fujita K, et al. Liver abscess caused by periodontal bacterial infection with Fusobacterium necrophorum. Hepatol Res 2011;41:194-6.

10.1111/j.1872-034X.2010.00748.x21269389
30

Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22:292-8.

10.1101/gr.126573.11122009990PMC3266036
31

Repass J, Maherali N, Owen K. Registered report: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Elife 2016;5:e10012.

10.7554/eLife.1001226882501PMC4764561
32

Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, et al. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21. Gastroenterology 2017;152:851-66.

10.1053/j.gastro.2016.11.01827876571PMC5555435
33

Warren RL, Freeman DJ, Pleasance S, Watson P, Moore RA, Cochrane K, et al. Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome 2013;1:16.

10.1186/2049-2618-1-1624450771PMC3971631
34

Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 2017;66:70-8.

10.1136/gutjnl-2015-30980026408641
35

Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012;22:299-306.

10.1101/gr.126516.11122009989PMC3266037
36

Marchesi JR, Dutilh BE, Hall N, Peters WH, Roelofs R, Boleij A, et al. Towards the human colorectal cancer microbiome. PLoS One 2011;6:e20447.

10.1371/journal.pone.002044721647227PMC3101260
37

Li YY, Ge QX, Cao J, Zhou YJ, Du YL, Shen B, et al. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J Gastroenterol 2016;22:3227-33.

10.3748/wjg.v22.i11.322727004000PMC4789998
38

McCoy AN, Araújo-Pérez F, Azcárate-Peril A, Yeh JJ, Sandler RS, Keku TO. Fusobacterium is associated with colorectal adenomas. PLoS One 2013;8:e53653.

10.1371/journal.pone.005365323335968PMC3546075
39

Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol 2015;1:653-61.

10.1001/jamaoncol.2015.137726181352PMC4537376
40

Wong SH, Kwong TNY, Chow TC, Luk AKC, Dai RZW, Nakatsu G, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut 2017;66:1441-8.

10.1136/gutjnl-2016-31276627797940PMC5530471
41

Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2016;65:1973-80.

10.1136/gutjnl-2015-31010126311717PMC4769120
42

Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 2014;74:1311-8.

10.1158/0008-5472.CAN-13-186524385213PMC4396185
43

Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14:195-206.

10.1016/j.chom.2013.07.01223954158PMC3770529
44

Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 2016;22:557-66.

10.3748/wjg.v22.i2.55726811607PMC4716059
45

Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012;10:575-82.

10.1038/nrmicro281922728587
46

Allen-Vercoe E, Strauss J, Chadee K. Fusobacterium nucleatum: an emerging gut pathogen? Gut Microbes 2011; 2:294-8.

10.4161/gmic.2.5.1860322067936
47

Shang FM, Liu HL. Fusobacterium nucleatum and colorectal cancer: A review. World J Gastrointest Oncol 2018;10:71-81.

10.4251/wjgo.v10.i3.7129564037PMC5852398
48

Xie G, Huang J, Zhang Q, Han N, Shi C, Wang X. Development and validation of a TaqMan™ fluorescent quantitative real-time PCR assay for the rapid detection of Edwardsiella tarda. Acta Oceanol Sin 2012;3:140-8.

10.1007/s13131-012-0227-7
49

Suehiro Y, Sakai K, Nishioka M, Hashimoto S, Takami T, Higaki S, et al. Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population. Ann Clin Biochem 2017;54:86-91.

10.1177/000456321664397027126270
50

Mima K, Cao Y, Chan AT, Qian ZR, Nowak JA, Masugi Y, et al. Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol 2016;7:e200.

51

Jiao H, Weng WC, Wang FJ, Cheng G, Wang W, Xie J. [Faster detection of Vibrio parahaemolyticus in foods by FQ-PCR technique]. Wei Sheng Yan Jiu. 2005;34:457-60.

52

Singh G, Sithebe A, Enitan AM, Kumari S, Bux F, Stenström TA. Comparison of droplet digital PCR and quantitative PCR for the detection of Salmonella and its application for river sediments. J Water Health 2017;15:505-8.

10.2166/wh.2017.25928771147
53

Koi M, Okita Y, Carethers JM. Fusobacterium nucleatum Infection in Colorectal Cancer: Linking Inflammation, DNA Mismatch Repair and Genetic and Epigenetic Alterations. J Anus Rectum Colon 2018;2:37-46.

10.23922/jarc.2017-05530116794PMC6090547
54

Zhang S, Cai S, Ma Y. Association between Fusobacterium nucleatum and colorectal cancer: Progress and future directions. J Cancer 2018;9:1652-9.

10.7150/jca.2404829760804PMC5950595
55

Coppenhagen-Glazer S, Sol A, Abed J, Naor R, Zhang X, Han YW, et al. Fap2 of Fusobacterium nucleatum is a galactose-inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth. Infect Immun 2015; 83:1104-13.

10.1128/IAI.02838-1425561710PMC4333458
56

Han YW. Fusobacterium nucleatum: a commensal-turned pathogen. Curr Opin Microbiol 2015;23:141-7.

10.1016/j.mib.2014.11.01325576662PMC4323942
57

Liu H, Redline RW, Han YW. Fusobacterium nucleatum induces fetal death in mice via stimulation of TLR4-mediated placental inflammatory response. J Immunol 2007;179:2501-8.

10.4049/jimmunol.179.4.250117675512
58

Fardini Y, Wang X, Témoin S, Nithianantham S, Lee D, Shoham M, et al. Fusobacterium nucleatum adhesin FadA binds vascular endothelial cadherin and alters endothelial integrity. Mol Microbiol 2011;82:1468-80.

10.1111/j.1365-2958.2011.07905.x22040113PMC3237733
59

Témoin S, Wu KL, Wu V, Shoham M, Han YW. Signal peptide of FadA adhesin from Fusobacterium nucleatum plays a novel structural role by modulating the filament's length and width. FEBS Lett 2012;586:1-6.

10.1016/j.febslet.2011.10.04722108653PMC3249520
60

Xu M, Yamada M, Li M, Liu H, Chen SG, Han YW. FadA from Fusobacterium nucleatum utilizes both secreted and nonsecreted forms for functional oligomerization for attachment and invasion of host cells. J Biol Chem 2007;282:25000-9.

10.1074/jbc.M61156720017588948
61

Chen Y, Peng Y, Yu J, Chen T, Wu Y, Shi L, et al. Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade. Oncotarget 2017;8:31802-14.

10.18632/oncotarget.1599228423670PMC5458249
62

Abed J, Emgård JE, Zamir G, Faroja M, Almogy G, Grenov A, et al. Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. Cell Host Microbe 2016;20:215-25.

10.1016/j.chom.2016.07.00627512904PMC5465824
63

Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer 2020;8:e000957.

10.1136/jitc-2020-00095732900861PMC7477968
64

Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 2015;42:344-55.

10.1016/j.immuni.2015.01.01025680274PMC4361732
65

Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015;148:77-87.

10.1053/j.gastro.2014.09.03825280443PMC4274235
66

Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-54.

10.1136/gutjnl-2011-30086522427238PMC3345105
67

Leung A, Tsoi H, Yu J. Fusobacterium and Escherichia: models of colorectal cancer driven by microbiota and the utility of microbiota in colorectal cancer screening. Expert Rev Gastroenterol Hepatol 2015;9:651-7.

10.1586/17474124.2015.100174525582922
68

Toiyama Y, Okugawa Y, Goel A. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun 2014;455:43-57.

10.1016/j.bbrc.2014.08.00125128828PMC4250419
69

Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhão JG, et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal 2011;4:ra75.

10.1126/scisignal.200186822087031PMC5029092
70

Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010;11:141-7.

10.1038/ni.182819946272
71

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36.

10.1001/jama.299.4.42518230780PMC2614237
72

Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011;11:519-31.

10.1038/nri302421785456
73

Edin S, Wikberg ML, Dahlin AM, Rutegård J, Öberg Å, Oldenborg PA, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 2012;7:e47045.

10.1371/journal.pone.004704523077543PMC3471949
74

Chen T, Li Q, Wu J, Wu Y, Peng W, Li H, et al. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism. Cancer Immunol Immunother 2018;67:1635-46.

10.1007/s00262-018-2233-x30121899
75

Abe K. Butyric acid induces apoptosis in both human monocytes and lymphocytes equivalently. J Oral Sci 2012;54:7-14.

10.2334/josnusd.54.722466881
76

Xue Y, Xiao H, Guo S, Xu B, Liao Y, Wu Y, et al. Indoleamine 2,3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages. Cell Death Dis 2018;9:355.

10.1038/s41419-018-0389-029500439PMC5834448
77

Kaplan CW, Ma X, Paranjpe A, Jewett A, Lux R, Kinder-Haake S, et al. Fusobacterium nucleatum outer membrane proteins Fap2 and RadD induce cell death in human lymphocytes. Infect Immun 2010;78:4773-8.

10.1128/IAI.00567-1020823215PMC2976331
78

Chen T, Li Q, Zhang X, Long R, Wu Y, Wu J, et al. TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection. Hum Pathol 2018;79:93-101.

10.1016/j.humpath.2018.05.00829792893
79

Huynh T, Kapur RV, Kaplan CW, Cacalano N, Kinder Haake S, Shi W, et al. The role of aggregation in Fusobacterium nucleatum- induced immune cell death. J Endod 2011;37:1531-5.

10.1016/j.joen.2011.06.03422000457
80

Shenker BJ, Datar S. Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle. Infect Immun 1995;63:4830-6.

10.1128/iai.63.12.4830-4836.19957591143
81

Shenker BJ, DiRienzo JM. Suppression of human peripheral blood lymphocytes by Fusobacterium nucleatum. J Immunol 1984;132:2357-62.

82

Bashir A, Miskeen AY, Hazari YM, Asrafuzzaman S, Fazili KM. Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut. Tumour Biol 2016;37:2805-10.

10.1007/s13277-015-4724-026718210
83

Guevarra LA Jr, Afable ACF, Belza PJO, Dy KJS, Lee SJQ, Sy-Ortin TT, et al. Immunogenicity of a Fap2 peptide mimotope of Fusobacterium nucleatum and its potential use in the diagnosis of colorectal cancer. Infect Agent Cancer 2018;13:11.

10.1186/s13027-018-0184-729619076PMC5879760
84

Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007;204:1757-64.

10.1084/jem.2007059017620361PMC2118683
85

Rao HL, Chen JW, Li M, Xiao YB, Fu J, Zeng YX, et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis. PLoS One 2012;7:e30806.

10.1371/journal.pone.003080622295111PMC3266280
86

Seow HF, Yip WK, Fifis T. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016;9:1899-920.

10.2147/OTT.S9510127099521PMC4821380
87

Temraz S, Mukherji D, Alameddine R, Shamseddine A. Methods of overcoming treatment resistance in colorectal cancer. Crit Rev Oncol Hematol 2014;89:217-30.

10.1016/j.critrevonc.2013.08.01524075059
88

Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett 2016;380:205-15.

10.1016/j.canlet.2015.07.04426272180
89

Ulivi P, Marisi G, Passardi A. Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget 2016;7:46678-91.

10.18632/oncotarget.871227081084PMC5216829
90

Feng PH, Yu CT, Chen KY, Luo CS, Wu SM, Liu CY, et al. S100A9(+) MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB. Oncotarget 2018;9:7631-43.

10.18632/oncotarget.2414629484139PMC5800931
91

Romano A, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, et al. PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy. Expert Rev Mol Diagn 2018;18:675-83.

10.1080/14737159.2018.147092929707981
92

Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009;104:739-50.

10.1038/ajg.2009.10419240699
93

Sung JJ, Ng SC, Chan FK, Chiu HM, Kim HS, Matsuda T, et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut 2015;64:121-32.

10.1136/gutjnl-2013-30650324647008
94

Amitay EL, Werner S, Vital M, Pieper DH, Höfler D, Gierse IJ, et al. Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. Carcinogenesis 2017;38:781-8.

10.1093/carcin/bgx05328582482
95

Kurt M, Yumuk Z. Diagnostic accuracy of Fusobacterium nucleatum IgA and IgG ELISA test in colorectal cancer. Sci Rep. 2021;11:1608.

10.1038/s41598-021-81171-133452405PMC7811007
96

Wang HF, Li LF, Guo SH, Zeng QY, Ning F, Liu WL, et al. Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer. Sci Rep 2016;6:33440.

10.1038/srep3344027678333PMC5039407
97

Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009;150:162-9.

10.7326/0003-4819-150-3-200902030-0000519189905
98

Tunsjø HS, Gundersen G, Rangnes F, Noone JC, Endres A, Bemanian V. Detection of Fusobacterium nucleatum in stool and colonic tissues from Norwegian colorectal cancer patients. Eur J Clin Microbiol Infect Dis 2019;38:1367-76.

10.1007/s10096-019-03562-731025134
99

Huang S, Yang Z, Zou D, Dong D, Liu A, Liu W, et al. Rapid detection of nusG and fadA in Fusobacterium nucleatum by loop-mediated isothermal amplification. J Med Microbiol 2016;65:760-9.

10.1099/jmm.0.00030027339262
100

Liu L, Tabung FK, Zhang X, Nowak JA, Qian ZR, Hamada T, et al. Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum. Clin Gastroenterol Hepatol 2018;16:1622-31.

10.1016/j.cgh.2018.04.03029702299PMC6151288
101

Tabung FK, Liu L, Wang W, Fung TT, Wu K, Smith-Warner SA, et al. Association of Dietary Inflammatory Potential With Colorectal Cancer Risk in Men and Women. JAMA Oncol 2018;4:366-73.

10.1001/jamaoncol.2017.484429346484PMC5844836
102

Berg A. Nutrition, development, and population growth. Popul Bull 1973;29:3-37.

103

Mafiana RN, Al Lawati AS, Waly MI, Al Farsi Y, Al Kindi M, Al Moundhri M. Association between Dietary and Lifestyle Indices and Colorectal Cancer in Oman: A Case-Control Study. Asian Pac J Cancer Prev 2018;19:3117-22.

10.31557/APJCP.2018.19.11.311730486551PMC6318402
104

Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology 2015;148:1244-60.

10.1053/j.gastro.2014.12.03525575572PMC4409470
105

Ali I, Koh YS. High-fat-diet-modulated Gut Microbiota Promotes Intestinal Carcinogenesis. J Bacteriol Virol 2015;45:394-6.

10.4167/jbv.2015.45.4.394
106

David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505:559-63.

10.1038/nature1282024336217PMC3957428
107

Xu Z, Knight R. Dietary effects on human gut microbiome diversity. Br J Nutr 2015;113:S1-5.

10.1017/S000711451400412725498959PMC4405705
108

Tabung FK, Smith-Warner SA, Chavarro JE, Wu K, Fuchs CS, Hu FB, et al. Development and Validation of an Empirical Dietary Inflammatory Index. J Nutr 2016;146:1560-70.

10.3945/jn.115.22871827358416PMC4958288
109

O'Keefe SJ, Li JV, Lahti L, Ou J, Carbonero F, Mohammed K, et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun. 2015;6:6342.

10.1038/ncomms734225919227PMC4415091
110

Mehta RS, Nishihara R, Cao Y, Song M, Mima K, Qian ZR, et al. Association of dietary patterns with risk of colorectal cancer subtypes classified by Fusobacterium nucleatum in tumor tissue. JAMA Oncol 2017;3:921-7.

10.1001/jamaoncol.2016.637428125762PMC5502000
111

Dharmani P, Strauss J, Ambrose C, Allen-Vercoe E, Chadee K. Fusobacterium nucleatum infection of colonic cells stimulates MUC2 mucin and tumor necrosis factor alpha. Infect Immun 2011;79:2597-607.

10.1128/IAI.05118-1121536792PMC3191979
112

Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 2018;18:309-24.

10.1038/nri.2017.14229379212
113

Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol 2012;30:677-706.

10.1146/annurev-immunol-020711-07500822224761
114

Lasry A, Zinger A, Ben-Neriah Y. Inflammatory networks underlying colorectal cancer. Nat Immunol 2016;17:230-40.

10.1038/ni.338426882261
115

Williams CS, Shattuck-Brandt RL, DuBois RN. The role of COX-2 in intestinal cancer. Expert Opin Investig Drugs 1999;8:1-12.

10.1517/13543784.8.1.115992053
116

Huang WW, Hsieh KP, Huang RY, Yang YH. Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study. Kaohsiung J Med Sci 2017;33:308-14.

10.1016/j.kjms.2017.03.00428601236
117

Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989;157:175-9.

10.1016/0002-9610(89)90442-X
118

Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.

10.1016/S0140-6736(10)61543-7
119

Johnson CC, Jankowski M, Rolnick S, Yood MU, Alford SH. Influence of NSAID Use Among Colorectal Cancer Survivors on Cancer Outcomes. Am J Clin Oncol 2017;40:370-4.

10.1097/COC.000000000000016425503426PMC4465051
120

Tsoi KK, Chan FC, Hirai HW, Sung JJ. Risk of gastrointestinal bleeding and benefit from colorectal cancer reduction from long-term use of low-dose aspirin: A retrospective study of 612 509 patients. J Gastroenterol Hepatol 2018;33:1728-36.

10.1111/jgh.1426129665624
121

Bos CL, Kodach LL, van den Brink GR, Diks SH, van Santen MM, Richel DJ, et al. Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene 2006;25:6447-56.

10.1038/sj.onc.120965816878161
122

Ma X, Aoki T, Tsuruyama T, Narumiya S. Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth. Cancer Res 2015;75:2822-32.

10.1158/0008-5472.CAN-15-012526018088
123

Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017;358:1443-8.

10.1126/science.aal524029170280PMC5823247
124

Haak BW, Lankelma JM, Hugenholtz F, Belzer C, de Vos WM, Wiersinga WJ. Long-term impact of oral vancomycin, ciprofloxacin and metronidazole on the gut microbiota in healthy humans. J Antimicrob Chemother 2019;74:782-6.

10.1093/jac/dky47130418539
125

Bever KM, Le DT. An Expanding Role for Immunotherapy in Colorectal Cancer. J Natl Compr Canc Netw 2017;15:401-10.

10.6004/jnccn.2017.003728275038
126

Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin 2017;67:326-44.

10.3322/caac.2139828481406PMC5530583
127

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol 2017;2017: PO.17.00029.

128

Cramer P, Bresalier RS. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. Curr Gastroenterol Rep 2017;19:3.

10.1007/s11894-017-0540-628124291
129

Nedaeinia R, Sharifi M, Avan A, Kazemi M, Nabinejad A, Ferns GA, et al. Inhibition of microRNA-21 via locked nucleic acid-anti-miR suppressed metastatic features of colorectal cancer cells through modulation of programmed cell death 4. Tumour Biol 2017;39:1010428317692261.

10.1177/101042831769226128347230
130

Kumar A, Thotakura PL, Tiwary BK, Krishna R. Target identification in Fusobacterium nucleatum by subtractive genomics approach and enrichment analysis of host-pathogen protein-protein interactions. BMC Microbiol 2016;16:84.

10.1186/s12866-016-0700-027176600PMC4866016
Information
  • Publisher :The Korean Society for Microbiology and The Korean Society of Virology
  • Publisher(Ko) :대한미생물학회‧대한바이러스학회
  • Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • Volume : 51
  • No :2
  • Pages :39-53
  • Received Date : 2021-04-30
  • Revised Date : 2021-06-10
  • Accepted Date : 2021-06-11
  • DOI :https://doi.org/10.4167/jbv.2021.51.2.039
Journal Informaiton JOURNAL OF BACTERIOLOGY AND VIROLOGY JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • NRF
  • 임플란트학회 전용 배너
  • KOFST
  • crossref crossmark
  • crossref cited-by
  • crossref funder-registry
  • crosscheck
  • orcid
  • open access
  • ccl
Journal Informaiton Journal Informaiton - close